DDInter1206 DDInter1652
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Mexiletine {u} (Compound) resembles {v} (Compound) Tocainide
Mexiletine {u} (Compound) binds {v} (Gene) AHR
Mexiletine {u} (Compound) upregulates {v} (Gene) CNOT4
Mexiletine {u} (Compound) downregulates {v} (Gene) ITGB1BP1
Mexiletine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Mexiletine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Mexiletine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methionine
Mexiletine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Mexiletine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Mexiletine {u} may lead to a major life threatening interaction when taken with {v} Theophylline
Mexiletine (Compound) resembles Tocainide (Compound)
Mexiletine (Compound) binds AHR (Gene)
Mexiletine (Compound) upregulates CNOT4 (Gene)
Mexiletine (Compound) downregulates ITGB1BP1 (Gene)
Mexiletine (Compound) causes Thrombocytopenia (Side Effect)
Mexiletine may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride
Mexiletine may cause a minor interaction that can limit clinical effects when taken with Methionine
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Mexiletine may lead to a major life threatening interaction when taken with Theophylline